<DOC>
	<DOCNO>NCT01817283</DOCNO>
	<brief_summary>This study prospective , multicenter , randomize , placebo-controlled clinical trial , evaluate impact Triptolide wilfordii T cell immune activation inflammation biomarkers HIV-infected immunological non-responders .</brief_summary>
	<brief_title>Impact T Cell Immune Activation Inflammation Triptolide Woldifii HIV-infected Immunological Non-responders</brief_title>
	<detailed_description>About 120 patient recruit 4 HIV/AIDS clinical center China randomize 1:1 intervention group placebo-controlled group . Triptolide wilfordii ( 20mg tid po ) would give invention group 24 week . T cell activation inflammation biomarkers include CD8+HLA-DR+CD38+ , IL-6 , D-Dimer high-sensitivity C-reactive protein ( hsCRP ) , protein degradation-1 ( PD-1 ) , Ki67 , soluble CD14 CD163 , PD-1 , CCR5 CD57 would test . Patients placebo-controlled group change take Triptolide wilfordii ( 20mg tid po ) another 24 week . All patient follow till 48 week . We hypothesis Triptolide wilfordii might reduce immune activation inflammation HIV immunological non-responders increase CD4 T cell count , provide new strategy treatment HIV-infected immunological non-responders .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Triptolide</mesh_term>
	<criteria>Continuous antiretroviral therapy &gt; 24 month ， consistent HIVRNA &lt; 40 copies/mL 12 month ; 1865 year old ; Male female ; Good adherence promise followup ; Inform Consent sign ; CD4 T cell less 250/ul . Active opportunistic infection ( stable within 4 week 2 week ) AIDSrelated carcinoma ; hemoglobin ( HGB ) &lt; 9 g/dl 、 white blood cell ( WBC ) &lt; 2000/ul 、 granulin ( GRN ) &lt; 1000 /ul 、 platelet ( PLT ) &lt; 75000 /ul 、 Cr &gt; 1.5x ULN 、 ALT AST alkaline phosphatase ( ALP ) &gt; 3x upper limit normal ( ULN ) 、 total bilirubin ( TBIL ) &gt; 2x ULN 、 creatine kinase ( CK ) &gt; 2x ULN ; Pregnant breastfeed woman woman pregnancy plan ; Active druguser ; Severe neurological defect ; Active alcohol abuse ; Severe gastrointestinal ulcer . Endstage disease cirrhosis , chronic obstructive pulmonary disease , congestive heart failure , recent myocardial ischemia , tumor , etc Those undertaking steroid , immunomodulator , antiinflammatory agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>HIV-infected immunological non-responders</keyword>
	<keyword>Triptolide</keyword>
	<keyword>immune activation</keyword>
	<keyword>inflammation</keyword>
	<keyword>CD4 T cell</keyword>
</DOC>